Literature DB >> 20470237

Cellular and cytokine changes in the alveolar environment among immunocompromised patients during Pneumocystis jirovecii infection.

Xavier Iriart1, Benoit Witkowski, Caroline Courtais, Sarah Abbes, Jean Tkaczuk, Monique Courtade, Sophie Cassaing, Judith Fillaux, Antoine Blancher, Jean-François Magnaval, Bernard Pipy, Antoine Berry.   

Abstract

Limited data exist on the cytokine and cellular changes in the alveolar environment in immunocompromised patients during Pneumocystis jirovecii infection. A cellular and a cytokine analysis were performed on bronchoalveolar lavage (BAL) samples from three groups of patients, i.e., an initial study group of 64 immunocompromised P. jirovecii-positive individuals and two control groups of P. jirovecii-negative patients who had been or not immunosuppressed (65 patients). The results were related to alveolar dilution as determined by urea measurement. Compared with non-infected groups, P. jirovecii-infected patients had a lower level of alveolar macrophages (AM), particularly those with high burdens of P. jirovecii. Alveolar macrophages over-expressed the Dectin-1 receptor, which was largely implicated in P. jirovecii clearance. The alveolar CD8+T and CD4+T lymphocyte counts were increased and an inverse correlation was observed between the alveolar CD4+ cell count and the P. jirovecii burden. Although the alveolar IL-6 level was considerably increased, alveolar IL-17, IL-10, TNF-α, TGF-β concentrations of P. jirovecii patients were not different from the control groups. Changes in the pulmonary environment were also highlighted during P. jirovecii colonization. Our study suggests that there is a correlation between the P. jirovecii burden in the alveolus (from colonization to a high P. jirovecii burden), and the degree of impairment of the alveolar immune response.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20470237     DOI: 10.3109/13693786.2010.484027

Source DB:  PubMed          Journal:  Med Mycol        ISSN: 1369-3786            Impact factor:   4.076


  10 in total

1.  Supplementary Role of Immunological Indicators in the Diagnosis and Prognosis of Pneumocystis Pneumonia in Non-HIV Immunocompromised Patients.

Authors:  Yaoqian Cao; Jiayue Chen; Lixia Dong
Journal:  Infect Drug Resist       Date:  2022-08-21       Impact factor: 4.177

2.  Mechanisms of Action of Vitamin D as Supplemental Therapy for Pneumocystis Pneumonia.

Authors:  Guang-Sheng Lei; Chen Zhang; Bi-Hua Cheng; Chao-Hung Lee
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

3.  The impact of concomitant pulmonary infection on immune dysregulation in Pneumocystis jirovecii pneumonia.

Authors:  Chung-Wei Chou; Fang-Chi Lin; Han-Chen Tsai; Shi-Chuan Chang
Journal:  BMC Pulm Med       Date:  2014-11-19       Impact factor: 3.317

4.  Outcome and prognostic factors of Pneumocystis jirovecii pneumonia in immunocompromised adults: a prospective observational study.

Authors:  Benjamin Jean Gaborit; Benoit Tessoulin; Rose-Anne Lavergne; Florent Morio; Christine Sagan; Emmanuel Canet; Raphael Lecomte; Paul Leturnier; Colin Deschanvres; Lydie Khatchatourian; Nathalie Asseray; Charlotte Garret; Michael Vourch; Delphine Marest; François Raffi; David Boutoille; Jean Reignier
Journal:  Ann Intensive Care       Date:  2019-11-27       Impact factor: 6.925

5.  Increased mRNA expression of key cytokines among suspected cases of Pneumocystis jirovecii infection.

Authors:  Mohammad Y Alshahrani; Mohammed Alfaifi; Mesfer Al Shahrani; Abdulaziz S Alshahrani; Ali G Alkhathami; Ayed A Dera; Irfan Ahmad; Shadma Wahab; Mirza M A Beg; Ali Hakamy; Mohamed E Hamid
Journal:  BMC Infect Dis       Date:  2021-01-07       Impact factor: 3.090

Review 6.  Current State of Carbohydrate Recognition and C-Type Lectin Receptors in Pneumocystis Innate Immunity.

Authors:  Theodore J Kottom; Eva M Carmona; Andrew H Limper
Journal:  Front Immunol       Date:  2021-12-16       Impact factor: 7.561

7.  Plasma IL-6/IL-10 Ratio and IL-8, LDH, and HBDH Level Predict the Severity and the Risk of Death in AIDS Patients with Pneumocystis Pneumonia.

Authors:  Jia Sun; Junwei Su; Yirui Xie; Michael T Yin; Ying Huang; Lijun Xu; Qihui Zhou; Biao Zhu
Journal:  J Immunol Res       Date:  2016-08-07       Impact factor: 4.818

Review 8.  Pneumocystis Pneumonia in Solid-Organ Transplant Recipients.

Authors:  Xavier Iriart; Marine Le Bouar; Nassim Kamar; Antoine Berry
Journal:  J Fungi (Basel)       Date:  2015-09-28

9.  Circulating and Pulmonary T-cell Populations Driving the Immune Response in Non-HIV Immunocompromised Patients with Pneumocystis jirovecii Pneumonia.

Authors:  Nan-Nan Zhang; Xu Huang; Hui-Ying Feng; Lin-Na Huang; Jin-Gen Xia; Yan Wang; Yi Zhang; Xiao-Jing Wu; Min Li; Wei Cui; Qing-Yuan Zhan
Journal:  Int J Med Sci       Date:  2019-08-14       Impact factor: 3.738

10.  Pneumocystis jirovecii pneumonia: a proposed novel model of corticosteroid benefit.

Authors:  Amal A Gharamti; William Mundo; Daniel B Chastain; Carlos Franco-Paredes; Andrés F Henao-Martínez; Leland Shapiro
Journal:  Ther Adv Infect Dis       Date:  2021-07-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.